Gain insight to provide optimal care
Patients’ response to medications is not uniform. Not every drug works for every patient. Individual patients may respond differently to the same drug in terms of:
- Side effects
We are a pioneer in preemptive pharmacogenomics (PGx). Our comprehensive PGx solutions have the potential to help clinicians and healthcare organizations:
- Reduce ADRs; resulting in fewer ER visits and lower mortality rates
- Reduce length of stay (LOS)
- Lower readmission rate
- Reduce total cost per discharge
- Improve patient’s drug adherence
Institute Whole Pharmacogenomics Scan (WPS)
Interrogate a whole range of PGx variants in an individual patient and preemptively retrieve comprehensive PGx information for later use
Allow patient’s PGx profile to be available before clinical decisions are made regarding future medications
Embrace potentially life-saving clinical decisions regarding best treatment options
A leading U.S. pediatric hospital:
- Utilizing preemptive PGx for patient care using WPS and its predecessor since 20116,7
- Nearly 4,500 patients have benefited from the program as of November 20188
Read more on the value of preemptive PGx and how to overcome the challenges to integrate PGx into patient care:
Preemptive pharmacogenomics-working towards bringing timely, individually tailored, precision health care to patients
Elevate standard of care using our PGx testing results and recommendations based on peer-reviewed and evidence-based clinical practice guidelines and FDA label information.
At RPRD, we offer a wide range of PGx testing services.
- Spear BB, et al. Clinical Application of Pharmacogenetics. Trends Mol. Med. 2001 May;7(5):201-4.
- FDA “Preventable Adverse Drug Reactions.” 2018.
- Relling MV, et al. Pharmacogenomics in the Clinic. Nature. 2015 Oct;526(7573):343-50.
- Ji Y, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol. Diagn. 2016 May;18(3):438-46.
- Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015 Jan;55:89-106.
- Hoffman JM, et al. PG4KDS: a Model for the Clinical Implementation of Pre-emptive Pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):45-55.
- PG4KDS: Clinical Implementation of Pharmacogenetics.
Additional case example resource: https://www.stjude.org/research/clinical-trials/pg4kds-pharmaceutical-science/implementation-resources-for-professionals.html